Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BiGx who wrote (6910)	2/3/1999 9:28:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

BG, the ML report mentions the amounts as "profit" booked as part of their "Alliance Revenue". One could interpret this as meaning net profit. We won't know for sure what's their split after costs as we don't know Celebrex's profit margin. We should have some idea after next quarter's earnings reports of both companies. My guess is that PFE get 25%-30% of the net profit. Both PFE and Searle have invested in sales and marketing. $100 something million for licensing rights to a blockbuster drug for 17 years? That would be a steal. I recall that PFE's co-marketing agreement with WLA re. Lipitor gives WLA the right to choose a drug in PFE's pipeline to co-market. Don't know if there is a similar arragement with Searle. I should be interested in your and the thread's views. Anthony